XFORNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
X4 Pharmaceuticals, Inc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$2.75+0.16 (+6.18%)
Close on Oct 19, 2026
- Market cap
- $347.45M
- P/E (TTM)
- –
- Dividend yield
- –
X4 Pharmaceuticals, Inc revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Product revenue, net | $8.68M | $8.05M | $6.52M | $5.69M | $4.68M | $3.50M | $2.56M | 100.2% | +85.4% |
| License and other revenue | $7.17M | $964.00K | $28.59M | $28.29M | $28.09M | $27.87M | $0 | 82.7% | -74.5% |
By region
From the segment and revenue-disaggregation notes of X4 Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.